EEEmin Tamer Elkiran

Emin Tamer Elkiran

*This is an algorithmically generated author record based on publicly available information.

Emin Tamer Elkiran has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A retrospective multicenter study on solitary fibrous tumors: investigation of clinical features and management approaches

    by Serkan Yaşar, Feride Yılmaz, Gözde Yazıcı, Alper Kahvecioğlu, Yüksel Ürün, Hatice Bölek, Hilal Karakaş, Didem Şener Dede, Nuriye Yıldırım Özdemir, Volkan Aslan, et al.

    Aims: Solitary fibrous tumors are exceedingly rare neoplasms, for which surgical resection remains the cornerstone of treatment; however, long-term surveillance is imperative due to the significant risk of recurrence. We aimed to evaluate tumor characteristics and treatment responses in this multicenter study. Methods: Sixty-eight adult patients with histologically confirmed solitary fibrous tumor (SFT) diagnosed between 2010 and 2024 from seven cancer centers in Turkiye were included. Clinical and pathological features along with treatment outcomes were assessed. Results: The majority of patients (65/68 pts, 95%) presented with localized disease and underwent primary resection, while 3 patients had metastatic disease at the time of diagnosis. Further analyses were performed only in patients with localized disease. Median follow-up time was 41.7 months. All patients underwent primary surgery; R0 resection was achieved in most patients (66.2%). Five -year DFS and OS were 67% and 87%, respectively. DFS of extrameningeal SFTs was further evaluated according to clinicopathological variables. Low Ki-67 Labeling Index, low mitotic rate, and younger age were found to be associated with longer DFS. Response rates to first-line systemic therapy after recurrence was 27% with chemotherapy and while no objective responses were achieved with pazopanib. Two patients experienced disease control for up to 11 months with pazopanib. This study is limited by the relatively small sample size and the heterogeneity arising from the inclusion of both meningeal and extrameningeal tumors located at different anatomical sites. Conclusion: Localized SFTs usually have favorable prognosis. Patients with extrameningeal SFTs with younger age, low Ki-67 Index and low mitotic rate have longer survival. Once relapsed, repeat surgical resection should be pursued when possible. Response rates to systemic treatment is generally low.

  • Open Access

    Superiority of Pathologic Lymph Node Ratio over Positive Lymph Node Count in Operated Early-Stage Breast Cancer

    by Zuhat Urakçı, Muhammet Ali Kaplan, Zeynep Oruç, Mahmut Gümüş, Doğan Uncu, Senar Ebinç, Metin Özkan, Çağlayan Geredeli, Emin Tamer Elkıran, Sadullah Girgin

    AIM: In early-stage breast cancer, the axillary lymph nodes play a crucial role in determining the prognosis of the disease. The rate of lymph node involvement might be a more valuable prognostic factor than the number of positive lymph nodes. Therefore, we aimed to evaluate whether the lymph node ratio (LNR) is a superior prognostic indicator compared to the pathologic lymph node count in early-stage disease. METHODS: We included 3053 non-metastatic, lymph node-positive breast cancer patients who were treated and followed at 6 medical oncology centers in Türkiye between 2004–2018. Based on LNR, patients were classified into three risk groups: high (>0.65), intermediate (0.21–0.65), and low (≤0.20). RESULTS: Classification of patients according to the TNM8 system based on the number of positive lymph nodes revealed that pathologic lymph node count (pN)1 accounted for 49.0% (n = 1495), pN2 for 30.0% (n = 917), and pN3 for 21.0% (n = 641). Based on the LNR risk group, the low-risk group accounted for 45.4% (n = 1385), intermediate for 36.2% (n = 1105), and high for 18.4% (n = 563) of the total patients. For the entire patient cohort, the 5- and 10-year disease-free survival (DFS) were 93% and 67%, respectively, while overall survival (OS) rates were 95% and 75%, respectively. The median DFS for patients with N1, N2, and N3 disease was 149 months (94.2–203.7), 120.1 months (108.2–132.0), and 81.8 months (68.4–131.1), respectively (p < 0.001). The median DFS for the three LNR risk groups (low, intermediate, and high risk) was 148.9 months (95.3–202.6), 118.7 months (99.9–137.7), and 81.8 months (68.2–95.3) respectively. Increasing LNR rate was an independent prognostic factor for DFS, according to multivariate analysis (p < 0.001). Furthermore, the median DFS was 133 months for pathologic N1 patients in the LNR intermediate-high risk group, while the median DFS was not reached in patients with LNR and the pN2 low risk group (p = 0.034). CONCLUSIONS: This study confirms the significance of LNR as a prognostic factor for DFS. The results show that in certain specific subgroups, LNR provides more information than pathologic lymph node counts.


  • Open Access

    Acute sunitinib neurotoxicity

    by Ahmet Gulmez, Mustafa Dikilitas, Emin Tamer Elkiran, Hakan Harputluoglu


  • Kanserli Hastalarda Hastalık Algısı ve Yaşam Kalitesi

    by Tuğba MENEKLİ, Ferhan Doğan, Emin Tamer Elkiran

    Amaç: Bu araştırma kanserli hastalarda hastalık algısını ve yaşam kalitesini incelemek amacıyla tanımlayıcı olarak yapılmıştır.Materyal ve metod: Araştırmanın örneklemini Aralık 2019-Şubat 2020 tarihleri arasında bir eğitim araştırma hastanesinin onkoloji kliniğinde yatarak ve ayaktan tedavi gören 151 kanserli hasta oluşturmuştur. Veriler Kişisel Tanıtım Formu, Hastalık Algısı Ölçeği (HAÖ), Yaşam Kalitesi İndeksi –Kanser Versiyonu-III (QOL-CV) kullanılarak toplanmıştır. Veriler SPSS 25 programında tanımlayıcı istatistikler, Independent Samples t, Kruskal Wallis ve Mann- Whitney U ile değerlendirilmiştir.Bulgular: Hastaların % 58.3’ ünün kadın, %29.1’inin kolon kanseri olduğu ve %11.9’unun hastalık hakkında bilgi sahibi olmadığı bulunmuştur. HAÖ alt ölçeklerinden hastaların kişisel kontrol algısı puan ortalamasının (23.00 ± 3.35), QOL-CV alt ölçeklerinden ise aile alt ölçeği puan ortalamasının en yüksek (26.97±5.04) olduğu bulunmuştur. Toplam QOL-CV puan ortalaması ise 23.44±4.42 olarak saptanmıştır. Sonuç: Hastaların kişisel kontrol algısı ve yaşam kalitesi aile alt boyutu en yüksek, toplam yaşam kalitesi ise orta düzeydedir.


  • Open Access

    Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

    by İrFan Çi̇çİn, Aydın ÇİLTAŞ, Saadettin Kiliçkap, Berna Öksüzoğlu, Doğan UNCU, Mehmet Artaç, Havva Yeşi̇l Çinkir, Abdurrahman Işikdoğan, Faysal Dane, Mehmet Ali̇uStaoğlu, et al.

    For those who helped create the Genki Dama


  • Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients

    by Emin Tamer Elkiran, Anatolian Society of Medical Oncology Group, Mehmet Ali Kaplan, Alper Sevinc, Sercan Aksoy, Umut Demirci, Mesut Seker, Hakan Harputluoglu, Nuriye Yildirim Ozdemir, Feridun Isik, et al.

    Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 ± 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.


  • Open Access

    Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population

    by Emin T Elkiran, Nefsal Mar, Bilge Aygen, Ferit Gursu, Aziz Karaoglu, Suleyman Koca

    Lung cancer (LC) is the leading cause of cancer-related deaths. Oxidative DNA damage may contribute to the cancer risk. The antioxidant paraoxonase (PON1) is an endogenous free radical scavenger in the human body. The aim of this study was to determine serum PON1 and arylesterase (ARE) activities in patients with newly diagnosed LC.


  • Differential alteration of drug metabolizing enzyme activities after cyclohosphamide/adriamycin administation in breast cancer patients

    by T. Elkiran, H. Harputluoglu, U. Yasar, M.O. Babaoglu, A.K. Dincel, K. Altundag, Y. Ozisik, N. Guler, A. Bozkurt

    Cyclophosphamide (CPA) and adriamycin (ADR) are widely used drugs for cancer chemotherapy. It has been reported that CPA and ADR singly or in combination could alter activities of a variety of drug-metabolizing enzymes in animals via multiple mechanisms. However, the effects of CPA/ADR on drug metabolism are largely unknown in human beings. Losartan metabolism has been suggested as a marker for determination of CYP2C9 activity. Caffeine is a commonly used probe to assess the metabolic activities of CYP1A2, CYP2A6, N-acetyltransferase 2 (NAT2) and xanthine oxidase (XO). The present study was designed to analyze the effects of CPA/ADR on these drug-metabolizing enzymes by using losartan and caffeine as probe drugs. A single oral dose of 25 mg losartan and a cup of instant coffee was given to 15 breast cancer patients on three occasions (before, and 2-4 h and 3 weeks after the adjuvant CPA/ADR chemotherapy [600 mg CPA/m2/day, 60 mg ADR/m2/day]). Losartan, caffeine and their metabolites were analyzed by using high-pressure liquid chromatography. When compared with baseline, CYP1A2 activity was increased by 20% and CYP2C9 activity was decreased by 315% 3 weeks after the administration of CPA/ADR chemotherapy (p = 0.05). The chemotherapy did not change the activities of CYP2A6, NAT2 or XO. CPA/ADR treatment caused a differential effect on drug-metabolizing enzyme activities, and this may contribute to predicting the efficacy and toxicity of chemotherapeutics, as well as understanding the drug-drug interactions.